The House Judiciary Committee revealed Thursday that Pfizer’s former Global Head of Vaccines Research and Development, Dr.

Novavax Inc. jumped as US regulators fully approved its Covid vaccine, easing investors’ concerns after the clearance was ...

The GOP-led House Judiciary Committee is requesting records from Pfizer’s CEO and an interview with a former company ...

A former Pfizer scientist said the timing of the 2020 vaccine results “wasn’t a coincidence,” according to allegations ...

WASHINGTON (Reuters) -U.S. lawmakers on Thursday asked Pfizer Inc for information on alleged comments by a former executive ...

Novavax had expected full approval for broader use by April 1, after the FDA reviewed data from a 30,000-person clinical ...

While the clearance is only for use in certain groups, Novavax’s long-awaited OK is still seen by analysts as a “win” for the ...

The vaccine will only be available to those at high risk from COVID—excluding those who may need it to protect a relative or ...

The U.S. Food and Drug Administration approved Novavax's COVIDd-19 vaccine with age restrictions after a six-week delay.

The agency narrowed who can get the shot and added new study requirements that could cost the company tens of millions.

Novavax originally showed its vaccine was safe and effective in a 30,000-person clinical trial. The FDA had been on track to ...

The U.S. Food and Drug Administration approved Novavax’s Covid-19 vaccine, but limited its use to older adults and people over the age of 12 with conditions that put them at risk due to the illness.